C4 Therapeutics(CCCC) - 2024 Q4 - Annual Results

Exhibit 99.1 Cash, Cash Equivalents and Marketable Securities of $267.3 million as of December 31, 2024; Expected to Provide Runway into 2027 C4 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights CFT1946 Phase 1/2 Trial Continues to Progress Across Multiple Cohorts; Data in Melanoma and Colorectal Cancer Expected in Second Half of 2025 WATERTOWN, Mass., February 27, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biop ...